Crinetics Pharmaceuticals, Inc.
CRNXDelisted Sep 1, 2026- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001658247
Crinetics Pharmaceuticals, Inc. was delisted on Sep 1, 2026; its insiders filed their last Form 4 on Sep 1, 2026; 267 institutions reported holding it in 13F filings for Q2 2026, worth $4.63B in total; no superinvestor held it.
13F holders, Q4 2021
Institutional positions in Crinetics Pharmaceuticals, Inc. as of Dec 31, 2021. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 118
- +24 vs. Q3 2021
- Shares held
- 44.3M
- +10.6M (+31.6%) vs. Q3 2021
- Total value
- $1.26B
- +$548.4M (+77.4%) vs. Q3 2021
- New holders
- 31
- 59 more added
- Sold out
- 7
- 19 more reduced
Compare with Q3 2021: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting CRNX on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 267 | $4.63B |
| Q1 2026 | 244 | $4.46B |
| Q4 2025 | 242 | $5.20B |
| Q3 2025 | 225 | $4.49B |
| Q2 2025 | 222 | $3.01B |
| Q1 2025 | 227 | $3.42B |
| Q4 2024 | 247 | $5.10B |
| Q3 2024 | 235 | $4.32B |
| Q2 2024 | 234 | $3.69B |
| Q1 2024 | 203 | $3.76B |
| Q4 2023 | 181 | $2.51B |
| Q3 2023 | 172 | $2.04B |
| Q2 2023 | 140 | $974.1M |
| Q1 2023 | 129 | $884.3M |
| Q4 2022 | 122 | $1.00B |
| Q3 2022 | 122 | $1.01B |
| Q2 2022 | 111 | $944.5M |
| Q1 2022 | 116 | $997.4M |
| Q4 2021 | 118 | $1.26B |
| Q3 2021 | 94 | $708.2M |
| Q2 2021 | 83 | $616.9M |
| Q1 2021 | 80 | $465.3M |
Institutions, Q4 2021
Shares, value and share of portfolio for each institution holding Crinetics Pharmaceuticals, Inc.; share changes are against Q3 2021.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| EcoR1 Capital, LLC | 590,169 | $16.8M | 0.54% | +590,169 | New |
| Geode Capital Management, LLC | 698,738 | $19.9M | 0.00% | +178,741+34.4% | Added |
| Opaleye Management Inc. | 724,400 | $20.6M | 4.36% | +322,287+80.1% | Added |
| Baker Bros. Advisors LP | 827,480 | $23.5M | 0.11% | −93,176−10.1% | Reduced |
| 5AM Venture Management, LLC | 862,286 | $24.5M | 4.60% | −500,000−36.7% | Reduced |
| Wellington Management Group LLP | 1,070,272 | $30.4M | 0.00% | +157,201+17.2% | Added |
| Point72 Asset Management, L.P. | 1,104,476 | $31.4M | 0.14% | +654,676+145.5% | Added |
| State Street Corp | 1,300,374 | $36.9M | 0.00% | +184,515+16.5% | Added |
| Frazier Management LLC | 1,384,293 | $39.3M | 3.03% | +532,987+62.6% | Added |
| Deep Track Capital, LP | 1,900,000 | $54.0M | 3.99% | +1,900,000 | New |
| Bain Capital Life Sciences Investors, LLC | 2,029,701 | $57.7M | 4.57% | +350,000+20.8% | Added |
| Vanguard Group Inc | 2,096,898 | $59.6M | 0.00% | +421,017+25.1% | Added |
| BVF Inc | 3,003,879 | $85.3M | 3.10% | +2,050,000+214.9% | Added |
| OrbiMed Advisors LLC | 3,196,876 | $90.8M | 1.18% | +200,000+6.7% | Added |
| BlackRock Inc. | 3,276,170 | $93.1M | 0.00% | +659,331+25.2% | Added |
| FMR LLC | 3,722,295 | $105.8M | 0.01% | −704,139−15.9% | Reduced |
| Driehaus Capital Management LLC | 4,793,638 | $136.2M | 1.39% | +1,795,126+59.9% | Added |
| Perceptive Advisors LLC | 5,163,517 | $146.7M | 2.27% | +1,200,000+30.3% | Added |
| Vivo Capital, LLC | 0 | $0 | 0.00% | −517,280−100.0% | Sold out |
| Blackstone Group Inc. | 0 | $0 | 0.00% | −24,334−100.0% | Sold out |
| Point72 Hong Kong Ltd | 0 | $0 | 0.00% | −2,438−100.0% | Sold out |
| Meeder Asset Management Inc | 0 | $0 | 0.00% | −1,988−100.0% | Sold out |
| Jacobi Capital Management LLC | 0 | $0 | 0.00% | −1,500−100.0% | Sold out |
| Penserra Capital Management LLC | 0 | $0 | 0.00% | −885−100.0% | Sold out |
| Parallel Advisors, LLC | 0 | $0 | 0.00% | −6−100.0% | Sold out |